Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

NXTC – Nextcure Inc

NextCure, Inc.
NXTC
$0.45
Name : NextCure, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $12,622,590.00
EPSttm : -1.77
finviz dynamic chart for NXTC
NextCure, Inc.
$0.45
2.17%
$0.01

Float Short %

1.22

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

0.01

EPS Last/This Y

0.4

EPS This/Next Y

0.16

Price

0.46

Target Price

3

Analyst Recom

1

Performance Q

-15.21

Relative Volume

0.66

Beta

1.07

Ticker: NXTC




19 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02NXTC0.49940.000.0041
2025-06-03NXTC0.4740.000.0041
2025-06-04NXTC0.4780.000.0043
2025-06-05NXTC0.49760.000.0043
2025-06-06NXTC0.50.000.0043
2025-06-09NXTC0.54010.000.0043
2025-06-10NXTC0.5430.000.0046
2025-06-11NXTC0.61510.000.0049
2025-06-12NXTC0.65030.000.0049
2025-06-13NXTC0.68480.000.0049
2025-06-16NXTC0.5050.000.0059
2025-06-17NXTC0.45550.000.0062
2025-06-18NXTC0.4590.000.0062
2025-06-20NXTC0.48160.000.0062
2025-06-23NXTC0.4610.000.0042
2025-06-24NXTC0.480.000.0042
2025-06-25NXTC0.460.000.0043
2025-06-26NXTC0.46040.000.0043
2025-06-27NXTC0.460.000.0043
DateSymbolLastP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02NXTC0.4830.0- -1.58
2025-06-03NXTC0.4730.0- -1.58
2025-06-04NXTC0.4730.0- -1.58
2025-06-05NXTC0.5030.0- -1.58
2025-06-06NXTC0.4930.0- -1.58
2025-06-09NXTC0.5330.0- -1.58
2025-06-10NXTC0.5530.0- -1.58
2025-06-11NXTC0.6230.0- -1.58
2025-06-12NXTC0.6530.0- -1.58
2025-06-13NXTC0.7030.0- -1.58
2025-06-16NXTC0.5030.0- -1.58
2025-06-17NXTC0.4630.0- -1.58
2025-06-18NXTC0.4530.0- -1.58
2025-06-20NXTC0.4730.0- -1.58
2025-06-23NXTC0.4630.0- -1.58
2025-06-24NXTC0.4730.0- -1.58
2025-06-25NXTC0.4530.0- -1.58
2025-06-26NXTC0.4630.0- -1.58
2025-06-27NXTC0.4630.0- -1.58
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02NXTC0.00-7.221.48
2025-06-03NXTC0.00-7.221.48
2025-06-04NXTC0.00-7.221.48
2025-06-05NXTC0.00-7.221.48
2025-06-06NXTC0.00-7.221.48
2025-06-09NXTC0.00-7.221.48
2025-06-11NXTC0.00-7.220.33
2025-06-12NXTC0.00-7.220.33
2025-06-13NXTC0.00-7.220.33
2025-06-16NXTC0.00-7.220.33
2025-06-17NXTC0.00-7.220.33
2025-06-18NXTC0.00-7.220.33
2025-06-19NXTC0.00-7.220.33
2025-06-20NXTC0.00-7.220.33
2025-06-24NXTC0.00-7.220.33
2025-06-25NXTC0.00-7.220.33
2025-06-26NXTC0.00-7.221.22
2025-06-27NXTC0.00-7.221.22
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS

-0.39

Avg. EPS Est. Current Quarter

-0.39

Avg. EPS Est. Next Quarter

-0.39

Insider Transactions

Institutional Transactions

-7.22

Beta

1.07

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

5

Growth Score

20

Sentiment Score

41

Actual DrawDown %

98

Max Drawdown 5-Year %

-98.8

Target Price

3

P/E

Forward P/E

PEG

P/S

P/B

0.23

P/Free Cash Flow

EPS

-1.77

Average EPS Est. Cur. Y​

-1.58

EPS Next Y. (Est.)

-1.43

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.66

Return on Equity vs Sector %

-112.6

Return on Equity vs Industry %

-94.7

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

NextCure, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 43
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
stock quote shares NXTC – Nextcure Inc Stock Price stock today
news today NXTC – Nextcure Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch NXTC – Nextcure Inc yahoo finance google finance
stock history NXTC – Nextcure Inc invest stock market
stock prices NXTC premarket after hours
ticker NXTC fair value insiders trading